AskVantage

Biotech and enhanced humans

CRISPR gene editing tool shown to stop Coronavirus replication in human cells

By future standards today's medicines and treatments are old fashioned, and we have an increasing array of powerful new tools at our disposal.

Key takeaways

  • A little while ago scientists used gene editing tool CRISPR to create an E.Coli bacteria that was resistant to every known pathogen on Earth.
  • Specifically, their system uses an enzyme called Cas13b, which cleaves single strands of RNA, like those found in SARS-CoV-2, the virus that causes COVID-19.
  • The researchers also found that their method worked even when new mutations were introduced into the SARS-CoV-2 genome, including those seen in the alpha coronavirus variant, first discovered in the UK.
Cite or link to this article

Griffin, M. (2021) 'CRISPR gene editing tool shown to stop Coronavirus replication in human cells', 311 Institute, 23 July. Available at: https://www.311institute.com/crispr-gene-editing-tool-shown-to-stop-coronavirus-replication-in-human-cells/ (Accessed: 1 October 2026).

A little while ago scientists used gene editing tool CRISPR to create an E.Coli bacteria that was resistant to every known pathogen on Earth. Then, in 2018 a Chinese scientist used the same technology immorally on two unborn twins and made them resistant to a host of deadly diseases ranging from HIV to Meningitis. He was then arrested and jailed …

These two experiments show just how powerful CRISPR is, or could be, when it comes to helping create designer humans resistant to disease – albeit an ethical, moral, and legal minefield.

Now though in a continuation of this work scientists have harnessed CRISPR gene-editing technology to block the replication of the novel coronavirus in human cells — an approach that could one day serve as a new treatment for COVID-19 and hopefully future pandemics.

However, unlike the other experiments, the study was performed in lab dishes and has not yet been tested on real animals or people, meaning a treatment based on the method could be years away.

CRISPR is a tool that enables researchers to precisely edit DNA. It's based on a natural defense system used in bacteria that allows the microbes to target and destroy the genetic material of viruses, Live Science previously reported.

In the new study, published in the journal , the researchers used a CRISPR system that targets and destroys strands of RNA, rather than DNA. Specifically, their system uses an enzyme called Cas13b, which cleaves single strands of RNA, like those found in SARS-CoV-2, the virus that causes COVID-19.

The researchers designed CRISPR-Cas13b to target specific sites on the RNA of SARS-CoV-2; once the enzyme binds to the RNA, it destroys the part of the virus needed to replicate, according to a statement from the Peter MacCallum Cancer Centre in Victoria, Australia, which collaborated on the research.

"Once the virus is recognized, the CRISPR enzyme is activated and chops up the virus," study lead author Dr. Sharon Lewin, of the Peter Doherty Institute for Infection and Immunity at the University of Melbourne, told AFP.

The researchers also found that their method worked even when new mutations were introduced into the SARS-CoV-2 genome, including those seen in the alpha coronavirus variant, first discovered in the UK.

Effective COVID-19 vaccines are currently being distributed around the world, but there remains a "clear and urgent need" for effective treatments for the disease, the authors said. They noted that there are "serious concerns" that the virus will evolve to "escape" current vaccines.

An ideal treatment would be an antiviral drug that patients take shortly after being diagnosed with COVID-19.

"This approach — test and treat —  would only be feasible if we have a cheap, oral and non-toxic antiviral. That's what we hope to achieve one day with this gene scissors approach," Lewin told AFP.

Although the new study is a first step toward such a treatment, it will likely be years before this method could be turned into a treatment that's widely available, AFP reported. The researchers now plan to test the method in animal models, and eventually conduct clinical trials in people.

Medicines that use CRISPR technology have not yet been approved to treat any diseases, but multiple studies are underway to test CRISPR-based therapies in people as a treatment for various diseases, including cancer and HIV.

FAQ

Why does this matter?

By future standards today's medicines and treatments are old fashioned, and we have an increasing array of powerful new tools at our disposal.

Matthew Griffin

About the author

Matthew Griffin Founder, 311 Institute

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath."

Read full bio

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath." 15-time best selling author of the "Codex of the Future" series, Matthew is the Founder and Futurist in Chief of the 311 Institute, a global Futures and Deep Futures advisory firm working with royal households, world leaders, G7, G20, and G77 governments, NGOs, and multi-national mid and mega cap firms to help them explore, shape, and lead the next 50 years of business and society.

An award-winning YouTube creator with over a million followers, with an unrivalled global reach and impact, Matthew is a highly sought-after international keynote speaker, lecturer, and mentor who collaborates with global leaders through the United Nations Alliance of Civilizations (UNAOC) and United Nations General Assembly (UNGA) to shape pivotal initiatives such as the UN’s AI for Humanity program, the United Nations Conference of the Parties (UN COP), and the World Economic Forum in Davos.

As the former Global Head of Cloud, National Security, and Enterprise Sales for companies including Atos, Dell-EMC, and IBM, Matthew has a proven track record of building multi-billion dollar business units and turning failing divisions into market leaders. His ability to identify, analyse, and communicate the implications of hundreds of emerging technologies and trends is unparalleled, and his insights are trusted by many of the world’s most respected organisations, including ABB, Accenture, Adidas, AON, ARM, BCG, Centrica, Citi, Coca-Cola, Dentons, Deloitte, Dow Jones, EY, Google, KPMG, Lego, Legal & General, LinkedIn, Microsoft, PepsiCo, Qualcomm, RWE, Samsung, Siemens AG and Siemens Energy, T-Mobile, UBS, VISA, Walmart, Workday, Worldpay and many others.

Regularly featured in the global media including the AP, BBC, Bloomberg, CNBC, Discovery, Forbes, Khaleej Times, Telegraph, TIME, ViacomCBS, WIRED, and the WSJ, Matthews mission is to help organisations create a fair and sustainable future whose benefits are shared by everyone irrespective of their ability, background, or circumstances.

What future do you need to see?

Choose one to get started on biotech and enhanced humans and the future of your organisation.

Where should Matthew reply?

Takes 30 seconds. No obligation. Matthew replies quickly. Privacy

Tag Cloud

Sources and further reading

  1. S41467 021 24577 9 nature.com
  2. Discovery points targeted treatment covid 19 petermac.org
  3. Peter MacCallum Cancer Centre petermac.org
  4. 20210713 gene editing blocks virus transmission in human cells france24.com
  5. alpha coronavirus variant who.int

Source: first published by the 311 Institute on 23 July 2021. Cite as: Griffin, M. (2021). CRISPR gene editing tool shown to stop Coronavirus replication in human cells. 311 Institute. https://www.311institute.com/crispr-gene-editing-tool-shown-to-stop-coronavirus-replication-in-human-cells/

You are welcome to quote this article with credit and a link to the original.

Book a Keynote